Sort
4,870 grants matching “glp 1”
Effects Of GLP-1 On Glucose Homeostasis
$0Josephine M Egan · Aging · Z01 · FY2006 · AG
Optimal first line therapies for patients with Cardiovascular-Kidney-Metabolic (CKM) Syndrome.
$0Christianne L. Roumie · Veterans Health Administration · I01 · FY2025 · VA
EFFECTS OF GLP 1 ON INSULIN ACTION IN DIABETIC &NON DIABETIC SUBJECTS
$0Mayo Clinic Coll Of Medicine, Rochester · M01 · FY2002 · RR
Targeting Microvascular Contributors to Impaired Functional Exercise Capacity in Diabetes
$0Jane E Reusch · Va Eastern Colorado Health Care System · I01 · FY2018 · VA
Bladder Dysfunction and Dysregulation of Neurotransmission
$0Maryrose P Sullivan · Va Boston Health Care System · I01 · FY2023 · VA
Role of the Androgen Receptor in Insulin Secretion in the Male
$0Franck Mauvais-Jarvis · Southeast Louisiana Veterans Health Care · I01 · FY2023 · VA
GLP 1 ON GLUCOSE UPTAKE AND GLUCOSE OUTPUT IN OBESITY
$0Johns Hopkins University · M01 · FY2000 · RR
GLP 1 ON GLUCOSE UPTAKE AND GLUCOSE OUTPUT IN OBESITY
$0Johns Hopkins University · M01 · FY2000 · RR
GLUCAGON LIKE PEPTIDE 1 (GPL 1) IN GLUCOSE HOMEOSTASIS
$0University Of Washington · M01 · FY2000 · RR
EFFECTS OF GLP ON GLUCOSE EFFECTIVENESS
$0Mayo Clinic Coll Of Medicine, Rochester · M01 · FY2002 · RR
Role of the Androgen Receptor in Insulin Secretion in the Male
$0Franck Mauvais-Jarvis · Southeast Louisiana Veterans Health Care · I01 · FY2024 · VA
CORE--BIOPROCESS AND PURIFICATION
$0University Of Virginia Charlottesville · U54 · FY2001 · HD
Role of glucagon-like peptide-1 in prescription opioid relapse and pain
$0David Reiner · U.S. National Institute On Drug Abuse · FI2 · FY2018 · GM
03-DK-0245 (Effect of AC2993 (synthetic exendin-4) on pa
$0Kristina I Rother · Diabetes, Digestive, Kidney Diseases · Z01 · FY2006 · DK
Islet alterations in type 2 diabetes
$0Alvin Carter Powers · Veterans Health Administration · I01 · FY2023 · VA
Modulating prostaglandin E2 receptor activity to improve pancreatic islet function
$0Maureen A Gannon · Veterans Health Administration · I01 · FY2024 · VA
A New High-Level Disinfectant for Medical Instruments
$0Rann Research Corporation · R44 · FY2005 · CI
Bladder Dysfunction and Dysregulation of Neurotransmission
$0Maryrose P Sullivan · Va Boston Health Care System · I01 · FY2024 · VA
Neuroprotective And Neurorestorative Signaling Mechanism
$0Mark P Mattson · Aging · Z01 · FY2006 · AG
Islet Cell Transplantation For T1dm: Clinical Studies
$0Diabetes, Digestive, Kidney Diseases · Z01 · FY2003 · DK
Enteroendocrine cell reprogramming during intestinal injury
$0Brian David Muegge · St. Louis Va Medical Center · IK2 · FY2024 · VA
CORE--TRANSLATION RESEARCH
$0University Of Pennsylvania · P01 · FY2002 · CA
Mechanisms of glucagon-like peptide 1 (GLP-1) in fatty liver disease
$0Frank A. Anania · Veterans Health Administration · I01 · FY2016 · VA
Targeting Microvascular Contributors to Impaired Functional Exercise Capacity in Diabetes
$0Jane E Reusch · Va Eastern Colorado Health Care System · I01 · FY2024 · VA
Comparative Effectiveness and Safety of Newer and Older Antihyperglycemic Medications
$0Ziyad Al-Aly · St. Louis Va Medical Center · I01 · FY2021 · VA